The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Abstract
PURPOSE: To determine if apparent diffusion coefficient (ADC) histogram analysis can stratify progression-free survival in patients with recurrent glioblastoma multiforme (GBM) prior to bevacizumab treatment. MATERIALS AND METHODS: The study was approved by the institutional review board and was HIPAA compliant; informed consent was obtained. Bevacizumab-treated and control patients (41 per cohort) diagnosed with recurrent GBM were analyzed by using whole enhancing tumor ADC histograms with a two normal distribution mixture fitting curve on baseline (pretreatment) magnetic resonance (MR) images to generate ADC classifiers, including the overall mean ADC as well as the mean ADC from the lower curve (ADC(L)). Overall and 6-month progression-free survival (as defined by the Macdonald criteria) was determined by using Cox proportional hazard ratios and the Kaplan-Meier method with log-rank test. RESULTS: For bevacizumab-treated patients, the hazard ratio for progression by 6 months in patients with less than versus greater than mean ADC(L) was 4.1 (95% confidence interval: 1.6, 10.4), and there was a 2.75-fold reduction in the median time to progression. For the control patients, there was no significant difference in median time to progression for the patients with low versus high ADC(L) (hazard ratio, 1.8; 95% confidence interval: 0.9, 3.7). For bevacizumab-treated patients, pretreatment ADC more accurately stratified 6-month progression-free survival than did change in enhancing tumor volume at first follow-up (73% vs 58% accuracy, P = .034). CONCLUSION: Pretreatment ADC histogram analysis can stratify progression-free survival in bevacizumab-treated patients with recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
A Threshold Selection Method from Gray-Level Histograms
Otsu, N. (1979) · IEEE Transactions on Systems, Man, and Cybernetics · doi:10.1109/tsmc.1979.4310076 · Cited by 43,398
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
McLachlan, G., & Peel, D. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/0471721182 · Cited by 10,991
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Sugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Shigematu, Y., Hirai, T., Okuda, T., Liang, L., Ge, Y., Komohara, Y., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2 · Cited by 1,163
Cited by
Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
O'Connor, J. P. B., Rose, C. J., Waterton, J. C., Carano, R. A. D., Parker, G. J. M., & Jackson, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0990 · Cited by 677
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 368
Tissue mechanics regulate brain development, homeostasis and disease
Barnes, J. M., Przybyla, L., & Weaver, V. M. (2017) · Journal of Cell Science · doi:10.1242/jcs.191742 · Cited by 316
Carrillo, J. A., Lai, A., Nghiemphu, P. L., Kim, H. J., Phillips, H. S., Kharbanda, S., Moftakhar, P., Lalaezari, S., Yong, W., Ellingson, B. M., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2950 · Cited by 299
Self-citationLu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Metadata
- Authors
- Pope, W. B., Kim, H. J., Huo, J., Alger, J., Brown, M. S., Gjertson, D., Sai, V., Young, J. R., Tekchandani, L., Cloughesy, T., Mischel, P. S., Lai, A., Nghiemphu, P., Rahmanuddin, S., & Goldin, J.
- Venue
- Radiology
- Published
- 2009-07
- Volume
- 252
- Issue
- 1
- Pages
- 182-189
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2099059965
- Cited by
- 318
- References
- 30
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment. https://app.cochat.ai/papers/10.1148/radiol.2521081534
- The paper
- Pope, W. B., Kim, H. J., Huo, J., Alger, J., Brown, M. S., Gjertson, D., Sai, V., Young, J. R., Tekchandani, L., Cloughesy, T., Mischel, P. S., Lai, A., Nghiemphu, P., Rahmanuddin, S., & Goldin, J. (2009). Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment. Radiology. https://doi.org/10.1148/radiol.2521081534
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.